Menu

Intellia Therapeutics, Inc. (NTLA)

$8.26
+0.05 (0.61%)

Data provided by IEX. Delayed 15 minutes.

Market Cap

$886.7M

Enterprise Value

$473.6M

P/E Ratio

N/A

Div Yield

0.00%

Rev Growth YoY

+59.6%

Rev 3Y CAGR

+20.5%

Company Profile

At a glance

Intellia Therapeutics is at the forefront of gene editing, leveraging its proprietary CRISPR-based platform to develop potentially curative, one-time treatments for severe genetic diseases, notably hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis.

The company's lead HAE program, lonvo-z, has successfully completed Phase 3 enrollment ahead of schedule and is on track for a Biologics License Application (BLA) submission in the second half of 2026, with a U.S. commercial launch anticipated in the first half of 2027.

A significant challenge has emerged with nex-z, Intellia's ATTR amyloidosis program, which is currently under a clinical hold by the FDA following a Grade 4 liver transaminase elevation and patient death in the MAGNITUDE trial. This event has suspended dosing and screening, creating near-term uncertainty for the program's timeline.

Price Chart

Loading chart...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks